Marinus Verwijs - 19 Mar 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
CHIEF TECHNICAL OFFICER
Signature
/s/ George A Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
19 Mar 2024
Net transactions value
-$60,916
Form type
4
Filing time
20 Mar 2024, 18:00:31 UTC
Previous filing
24 Jan 2024
Next filing
03 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $77,327 +5,300 $14.59 5,300 19 Mar 2024 Direct F1
transaction AVTE Common Stock Sale $65,119 -2,536 -48% $25.68 2,764 19 Mar 2024 Direct F1, F2
transaction AVTE Common Stock Sale $73,124 -2,764 -100% $26.46 0 19 Mar 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -5,300 -5.9% $0.000000 84,700 19 Mar 2024 Common Stock 5,300 $14.59 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2023.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.255 to $26.125, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.30 to $26.71, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 25% of this option vested and became exercisable on March 21, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.